Study Summary
This trial is studying whether a blood pressure medication can help improve symptoms in people with postural tachycardia syndrome, which mostly affects young women and causes significant disability.
Eligible Conditions
- Postural Orthostatic Tachycardia Syndrome
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: after 30 min supine to after 15 min upright (delta VOSS), 2-3 hours after placebo or moxonidine intake [delta (delta VOSS)].
Hour 3
Change in Orthostatic Change in Heart Rate [delta (delta HR)]
Hour 3
Change in Orthostatic Symptom Burden [delta (delta VOSS)]
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Moxonidine
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group
48 Total Participants · 2 Treatment Groups
Primary Treatment: Moxonidine · Has Placebo Group · Phase < 1
Moxonidine
Drug
Experimental Group · 1 Intervention: Moxonidine · Intervention Types: DrugPlacebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: DrugTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Moxonidine
FDA approved
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: after 30 min supine to after 15 min upright (delta voss), 2-3 hours after placebo or moxonidine intake [delta (delta voss)].
Who is running the clinical trial?
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,592 Previous Clinical Trials
46,945,746 Total Patients Enrolled
10 Trials studying Postural Orthostatic Tachycardia Syndrome
442 Patients Enrolled for Postural Orthostatic Tachycardia Syndrome
Vanderbilt University Medical CenterLead Sponsor
774 Previous Clinical Trials
601,069 Total Patients Enrolled
15 Trials studying Postural Orthostatic Tachycardia Syndrome
711 Patients Enrolled for Postural Orthostatic Tachycardia Syndrome
André Diedrich, MDPrincipal InvestigatorVanderbilt University Medical Center
1 Previous Clinical Trials
48 Total Patients Enrolled
1 Trials studying Postural Orthostatic Tachycardia Syndrome
48 Patients Enrolled for Postural Orthostatic Tachycardia Syndrome
Eligibility Criteria
Age 18 - 55 · Female Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:able to provide information that allows for an informed decision to be made.
not feeling lightheaded or dizzy when standing up quickly;
normotension or hypertension (blood pressure ≤ 140/90 mmHg)
They do not feel lightheaded or dizzy when standing up quickly and their blood pressure is normal or high.
Hormones released from the ovaries during the follicular phase stimulate the growth of the ovarian follicle and the production of estrogen.
, are at high risk for developing POTS related adverse cardiovascular events
This study includes female and male subjects aged 18-55 years.
The text states that a heart rate increase of ≥30 beats/min within 10 minutes of upright posture is indicative of POTS.
You have chronic symptoms that last for at least 6 months and are not caused by any other condition.
Who else is applying?
What state do they live in?
| Hawaii | 100.0% |
How old are they?
| 18 - 65 | 100.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments